Study of Paclitaxel in Patients With Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Paclitaxel is one of the most widely used human anticancer agents. Paclitaxel has a low degree of solubility and Cremophor EL is typically used as the solubiliser. Cremophor EL is known to cause hypersensitivity reactions that can be life-threatening. As Paclical® does not contain Cremophor EL, hypersensitivity reactions can be expected to be less. PURPOSE: To study the efficay and safety of two different formulations of paclitaxel, Paclical® and Taxol®.

Official Title
-----------------
An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL)

Conditions
-----------------
Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

Intervention / Treatment
-----------------
* Drug: Paclical®
* Drug: Taxol®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological or cytological confirmed epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. Patients relapsing > 6 months after end of first line or second line treatment including platinum based therapy. Prior therapy and duration of response will be documented in the CRF for descriptive analysis. CA 125 >2 x upper normal limit (UNL) documented at two occasions, with more than one week interval, according to appendix I, patient groups A and B, measurable/non- measurable disease. Age > 18 years Eastern Cooperative Oncology Group (ECOG) performance score 0-2 Life expectancy >12 weeks Patient has blood counts at baseline of: Absolute neutrophil count (ANC) >1,5 x 109 / L. Platelet count >100 x 109 / L Haemoglobin (Hb) ≥9g/dl (can be post transfusion) Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) < 2 x UNL Total bilirubin ≤1.5 x UNL. Adequate renal function defined as serum creatinine < 2.0 mg/dl or 177μmol/l. Alkaline phosphatase (ALP) < 2.5 x UNL Signed informed consent obtained Exclusion Criteria: Patient has peripheral neuropathy of grade ≥ 2 per NCI-CTCAE version 3.0 Surgical procedure due to progressive disease within 4 weeks of any of the CA-125 measurements Patient receiving concurrent hormonal, immuno-, or radiotherapy. Treatment must have stopped for at least 4 weeks before start of drug treatment (Day 1, Cycle 1). Bowel obstruction at screening Tumours of other origin or histology Patient of child-bearing potential, not practising adequate contraception, or pregnant or lactating women Patient has a history of severe allergy or severe hypersensitivity to study drugs Any uncontrolled medical problem that in the opinion of the investigator would preclude safe administration of the study drugs, e.g. heart, lung or kidney disease, suspicion of brain metastasis or mental disorder to make the patient unable to participate in the study Participation in an investigational drug study within 4 weeks prior to study treatment (Day 1, Cycle 1)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Paclitaxel, micellar (Paclical®)<br> | Drug: Paclical®<br>* 250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle. Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.<br>|
| Active Comparator: Paclitaxel, CrEL (Taxol®)<br> | Drug: Taxol®<br>* 175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle. Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival (PFS). |  |  | 
| Change in Area under the curve of CA 125 |  |  | 
| Incidence and severity of hypersensitivity reactions |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nadir and time to nadir of CA 125 during and after treatment |  |  | 
| T½ of CA 125 |  |  | 
| Safety and tolerability |  |  | 
| Response rate using CA 125 |  |  | 
| Overall survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian Cancer